Previous studies have shown that the plasma level of soluble IgG Fc receptor type III (sFc␥RIII) is a measure of the total body neutrophil mass. The aim of this study was to determine whether the plasma level sFc␥RIII is associated with the risk of contracting bacterial infections in patients with neutropenia. We collected blood from 66 patients suffering from acquired idiopathic neutropenia, whose blood was sent to our laboratory for diagnostic evaluation of neutropenia (neutrophil count F1,500 cells/L). Soluble Fc␥RIII levels were measured in plasma. Genotype distibutions of Fc␥R polymorphisms were determined. Clinical data were obtained from the patient files. Patients were assessed as to whether or not they had suffered from a bacterial infection 3 months before to 3 months after a single sFc␥RIII measurement. In addition, longitudinal data were obtained from 21 patients. Of the 66 neutropenic patients who were included, 15 had suffered from a bacterial infection in the period 3 months before to 3 months after sFc␥RIII measurement. The age and sex distribution was equal among the groups with and without infections, as were the genotype frequencies of neutrophil Fc␥R polymorphisms. Both neutrophil count and plasma level sFc␥RIII were significantly lower in the patient group with infections, compared with the noninfected group (P ‫؍‬ .03 and P F .0001, respectively). No infections were reported for patients who had plasma sFc␥RIII levels above 100 arbitrary units (AU; normal value, 30 to 200). After matching each infected patient with two noninfected patients having the same neutrophil count, sFc␥RIII plasma levels remained significantly lower in the group with infections (P ‫؍‬ .0001). For the patients who were followed in time, no infections were reported when sFc␥RIII levels were above 100 AU. In conclusion, our population of patients with chronic idiopathic neutropenia with plasma sFc␥RIII levels above 100 AU did not show an increased risk of contracting bacterial infections.
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N EUTROPHILIC GRANULOCYTES play an important
role in the host defence against bacteria. Qualitative, as well as quantitative, neutrophil disorders increase the risk of contracting bacterial infections. Normally, the majority of body neutrophils is in the bone marrow storage pool, whereas circulating neutrophils comprise less than 5% of the total body amount of neutrophils. Nevertheless, it is well established that a low number of circulating neutrophils is correlated with an increased infection risk. Prophylactic treatment with antibiotics or with granulocyte colony-stimulating factor (G-CSF) is common practice in neutropenic patients, especially in case of severe neutropenia (Ͻ500/µL). Because not all neutropenic patients will contract a bacterial infection, prophylactic therapy is not always necessary. Therefore, a parameter that would allow a more adequate treatment indication would be welcome. Human neutrophils express two different IgG Fc receptors (Fc␥R) on their cytoplasmic membrane, both of which bind IgG complexes (reviewed in De Haas et al 1 ). These receptors play a crucial role in the process that leads to the degradation of IgG-opsonized particles. Each neutrophil carries 10,000 to 30,000 copies of Fc␥RIIa (CD32) and 100,000 to 300,000 copies of Fc␥RIIIb (CD16). Genetic polymorphisms on both Fc␥RIIIb and Fc␥RIIa influence the receptor-ligand interaction. [2] [3] [4] [5] Soluble (s) Fc␥RIII is present in plasma and other body fluids and is mainly derived from neutrophils. [6] [7] [8] Previous data suggest that the level of sFc␥RIII might be an additional parameter in the evaluation of quantitative neutrophil disorders. The concentration of sFc␥RIII in plasma correlates with the production of neutrophils in the bone marrow. 9 ,10 Depletion of the storage or marginating neutrophil pool does not affect plasma sFc␥RIII levels, whereas changes in bone marrow neutrophil production are followed by changes in plasma sFc␥RIII levels after a few days. 9, 10 Neutrophils release Fc␥RIIIb during apoptosis in vitro. 11 In vivo, the lag time between changes in number of circulating neutrophils and levels of sFc␥RIII suggests that plasma sFc␥RIII originates from apoptotic tissue neutrophils and that neutrophils have a tissue phase of approximately 6 days. From these data, we hypothesized that the level of sFc␥RIII in plasma of neutropenic patients could be used as an additional parameter to determine the total body neutrophil mass and thus the infection risk in these patients.
MATERIALS AND METHODS
Patients. EDTA-anticoagulated blood was sent to the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB) for diagnostic screening for the presence of neutrophil (auto)antibodies. Sixty-six consecutive adult patients (aged Ͼ18 years) with chronic (ie, Ն6 months) acquired idiopathic neutropenia were included from a total of approximately 300 diagnostic requests. Informed consent and clinical information was obtained via the treating physicians. Neutropenia was defined as an absolute neutrophil count (ANC) below 1,500/µL. No autoantibodies were detected in the direct immunofluorescence test. Patients were excluded when (1) the direct immunofluorescence test was positive, ie, the neutropenia was (auto)immunemediated, (2) another autoimmune disease or an immunodeficiency apart from neutropenia was present, or (3) the neutropenia was drug-induced. The patients were evaluated as to whether or not they had suffered from one or more bacterial infections in the period 3 months before until 3 months after analysis. Bacterial infections were scored on the basis of a positive bacterial culture result, in addition to clinical symptoms. None of the patients received prophylactic therapy. Twentyone patients were followed in time.
Cell separation. Blood from healthy controls or patients was centrifuged over a Ficoll-Hypaque gradient (Pharmacia Fine Chemicals, Uppsala, Sweden) with a specific gravity of 1.076 g/mL. Peripheral blood mononuclear cells (PBMC) were harvested from the interphase for DNA isolation. Erythrocytes in the pellet were lysed with isotonic NH 4 Cl at 4°C. The remaining cells were Ͼ95% neutrophils.
Soluble Fc␥RIII enzyme-linked immunosorbent assay (ELISA). Levels of sFc␥RIII in (EDTA-) plasma or serum were measured essentially as previously described. 12 Briefly, ELISA plates (Nunc Immunoplate Maxisorp, Rockslide, Denmark) were coated with 5 µg/mL CD16 monoclonal antibody (MoAb) CLBFcRgran1 in 0.1 mol/L NaHCO 3 , pH 9.6. Unbound sites were blocked with phosphate-buffered saline (PBS) containing 2% (vol/vol) milk (PBS/milk). Patient plasma samples were diluted in high performance ELISA (HPE) buffer (CLB, Amsterdam, The Netherlands). After washing the plates with PBS containing 0.02% Tween-20 (vol/vol), the wells were incubated with 25-fold and 50-fold dilutions of plasma or serum samples at room temperature in duplicate. The plates were then incubated for 1 hour with appropriate concentrations of a biotin-labeled polyclonal antipanFc␥RIII antibody, diluted in HPE buffer. After 30 minutes of incubation with horseradish peroxidase-labeled streptavidin, diluted in PBS/milk, 100 µL of substrate buffer was added. The colorimetric reaction was stopped by addition of 2 mol/L H 2 SO 4 , and the absorbance at 450 nm was measured in a Titertek multiscan ELISA reader (Flow Laboratory, Rockville, MD). Pooled plasma of 90 healthy individuals was used to obtain a calibration curve. The concentration of sFc␥RIII in this pool was set at 100 arbitrary units (AU; approximately 5 nmol/L; normal range, 30 to 200 AU; approximately 1.5 to 10 nmol/L). 12 Neutrophil Fc␥RIIIb-neutrophil antigen (NA) phenotyping. Neutrophils were phenotyped with NA1-and NA2-specific MoAbs by an indirect immunofluorescence test as described previously. 13 Briefly, neutrophils were incubated with MoAb for 30 minutes at room temperature and subsequently stained with fluorescein isothiocyanate (FITC)-labeled goat antimouse Ig. Binding of MoAbs was assessed by fluorescence microscopy. When the amount of isolated neutrophils was too small to perform phenotyping, genomic DNA was isolated from PBMC of the patient, and the genotype was determined by polymerase chain reaction (PCR). Previous work has shown that NA-genotyping and NA-phenotyping results are in complete concordance. 14 Neutrophil Fc␥RIIIB and Fc␥RIIA genotyping. Genotyping for the NA system on Fc␥RIIIb was performed as previously described, based on two PCR-based allele-specific primer annealing (ASPA) assays. 14 A new PCR-based allele-specific restriction analysis (ASRA) was developed to type for the Fc␥RIIA-131H/R polymorphism. Briefly, two Fc␥RIIA-specific primers were used to amplify a 77-bp fragment (sense: 5Ј-CAA GCC TCT GGT CAA GGT C-3Ј; antisense: 5Ј-TGG AGA AGG TGG GAT CCA TA-3Ј). The antisense primer introduced an NdeI restriction site only in Fc␥RIIA-131H. The amplified Fc␥RIIA-specific fragment was digested with restriction endonuclease NdeI after which fragments were electrophoresed in polyacrylamide gels and visualized with ethidium bromide and UV light. The Fc␥RIIA-131R/H gene frequencies in a healthy Caucasian population (n ϭ 93) were equal to the published ones. 2 Statistical analysis. GraphPad Instat (GraphPad Software, San Diego, CA) was used for statistical calculations. After initial analysis of all the included patients, each patient with an infection was matched with two patients without infections who had an equal ANC to correct for any effect of the neutrophil count on the infection incidence. Data were analyzed with Student's t test. When differences in standard deviations were significant, Welch's approximate t-test was used. Fc␥R genotype and phenotype distributions were compared with the 2 test. A two-sided P value below .05 was considered significant. When comparing the test characteristics of the ANC and the plasma sFc␥RIII level, receiver operating characteristics (ROC, ie, sensitivity v 1-specificity) curves were used to determine the optimal cut-off point of the ANC.
RESULTS
Sixty-six patients with neutropenia of unknown origin were divided in two groups who either did or did not suffer from a bacterial infection in the period 3 months before to 3 months after sFc␥RIII measurement. Table 1 shows the clinical and phenotypical data of all included patients. Fifteen patients suffered from a bacterial infection in the study period, as determined on the basis of the clinical picture and a positive culture. Among the diagnosed infections were recurrent upper respiratory tract infections (n ϭ 4), pneumonia (n ϭ 3), urinary tract infections (n ϭ 3, one urosepsis), recurrent skin infections (n ϭ 2), aphtous mouth ulcers (n ϭ 2), and infections of the gastrointestinal tract (n ϭ 1). All infections were treated successfully with antibiotics. As shown in Table 1 , no significant differences were observed regarding sex and age distribution among the two groups. Fifty-three patients were typed for the Fc␥RIIa-131R/H and the Fc␥RIIIb-NA(1,2) polymorphism. No genomic DNA was available from 13 patients. The Fc␥RIIA and Fc␥RIIIB genotype frequencies in the infected and noninfected groups were not significantly different and did not differ from frequencies in the normal (Dutch) population. 15 No differences were observed in sex and age between neutropenic patients with and without a bacterial infection 3 months before 
the sFc␥RIII measurement. The sFc␥RIII levels were significantly lower in the patients with infections compared with the patients without infections (49 Ϯ 26 AU v 109 Ϯ 66 AU, respectively; Welch's approximate t-test; P Ͻ .0001). As shown in Table 1 , the results of diagnostic bone marrow examinations were essentially the same in the two groups. The ratios between mitotic and postmitotic cells of the neutrophilic lineage were not available. Like the sFc␥RIII levels, the mean number of circulating neutrophils was significantly lower in the patients with infections, compared with the patients without infections (860 Ϯ 477 cells/µL and 1,170 Ϯ 320 cells/µL, respectively; Welch's approximate t-test; P ϭ .03). To identify the level of sFc␥RIII as an independent predictor of infection risk, 14 neutropenic patients with infections were each matched with two neutropenic patients without infections, but with equal ANC. The remaining patient (sFc␥RIII: 24 AU; ANC: 50 cells/µL) in the group with infections could not be matched and was excluded. Figure 1 shows the distribution of sFc␥RIII levels in plasma of neutropenic patients with and without bacterial infections, matched for ANC. The plasma levels of sFc␥RIII were significantly lower in the neutropenic patients with infections, compared with the uninfected patients (54 Ϯ 26 AU v 113 Ϯ 62 AU, respectively; Welch's approximate t-test; P ϭ .0001). The mean difference between sFc␥RIII levels in patients with and without infections was 59 AU (95% confidence interval [CI]: 31 to 87 AU). Again, no infections were reported for patients who had sFc␥RIII levels above 100 AU. All patients who suffered from an infection in the defined period had plasma sFc␥RIII levels below 100 AU. The level of sFc␥RIII was not statistically correlated to age or ANC. The two groups had similar phenotype distributions of the Fc␥RIIIb-NA and the Fc␥RIIa-131R/H polymorphisms.
We compared the prognostic values of a plasma level of sFc␥RIII below 100 AU and an ANC below 1000 cells/µL regarding the infection risk in the unmatched neutropenic patient group (n ϭ 66). The ANC cut-off point of 1,000 cells/µL was determined by ROC curves. This cut-off value resulted in optimal specificity and sensitivity in our patient group (not shown). As shown in Table 2 , the sensitivity and negative predictive value of the level of sFc␥RIII are both 1.0, using a cut-off point of 100 AU. The sensitivity and negative predictive value of the ANC, with a cut-off value of 1,000/µL, were 0.6 and 0.7, respectively.
Longitudinal data were obtained from 21 of the 66 patients (32%). These patients were followed for a mean period of 9.4 months (range, 1 to 17) in which at least two sFc␥RIII levels were measured (mean, 2.95; range, 2 to 5). Laboratory findings were correlated to the clinical situation of the patient at the time of blood sampling. To investigate whether sFc␥RIII levels were constant in the healthy population, five healthy individuals served as controls. Blood from these donors was collected every 3 months for 1 year, and neutrophil counts and plasma sFc␥RIII levels were measured. In these controls, both parameters remained constant over time, and no bacterial infections were reported in the study period (data not shown). The neutropenic patients were divided into three groups: a group with sFc␥RIII levels above 100 AU without infections, a group with sFc␥RIII levels below 100 AU without infections, and a group with sFc␥RIII below 100 AU with infections. As shown in Fig 2, sFc␥RIII levels above 100 AU were only observed in patients without infections. In 2 particular patients (Table 3 , data not plotted in Fig 2) , an increase in sFc␥RIII level to values above 100 AU was coincident with a resolution of infection periods (not shown).
DISCUSSION
Less than 5% of the total body amount of neutrophils circulate in the peripheral blood. Nevertheless, extremely low numbers of circulating neutrophils (Ͻ500/µL) correlate with the incidence of bacterial infections. 16 However, the infection risk in patients with moderate to mild neutropenia (500 to 1,500/µL) is difficult to estimate, and an additional parameter to evaluate the extent of neutrophil defense is desirable. Previous work has shown that the concentration of sFc␥RIII in plasma is a reflection of the total body neutrophil mass and is correlated *The optimal cut-off point for ANC was determined with ROC curve. †A positive test was defined as an sFcRIII level below 100 AU. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated with 2 ϫ 2 tables (infection v sFc␥III Ͻ 100: n ϭ 15, infection v sFc␥RIII Ͼ 100: n ϭ 0, no infection v sFc␥RIII Ͻ 100: n ϭ 30, no infection v sFc␥RIII Ͼ 100: n ϭ 21; infection v ANC Ͻ 1,000: n ϭ 9, infection v ANC Ͼ 1,000: n ϭ 6, no infection v ANC Ͻ 1,000: n ϭ 17, no infection v ANC Ͼ 1,000: n ϭ 34).
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with the production of neutrophils in the bone marrow. 9, 10 In the present study, we identified the concentration of sFc␥RIII in plasma as a parameter that can be of additional value in the prediction of the infection risk in patients with chronic idiopathic neutropenia. We tested the hypothesis that a normal sFc␥RIII level in plasma from neutropenic patients reflects a normal total body amount of neutrophils and therefore indicates a normal neutrophil defense and thus no increased infection risk. Patients with an established decrease in neutrophil production (due to malignancies in the bone marrow or drugs) or increased neutrophil destruction (due to circulating neutrophil antibodies) were excluded. The latter group of patients was excluded because part of the autoantibodies in immunemediated neutropenia has anti-Fc␥RIII specificity, 17 which might interfere with sFc␥RIII measurement. Moreover, the fate of Fc␥RIIIb derived from destroyed neutrophils is unknown, rendering interpretation of sFc␥RIII levels in plasma from patients with immune-mediated neutropenia difficult.
In 66 patients with neutropenia of unknown origin, no infections were reported when plasma sFc␥RIII levels were above 100 AU. Overall, the mean plasma sFc␥RIII level, as well as the mean neutrophil count, were significantly lower in neutropenic patients with infections compared with patients without infections. The lower plasma sFc␥RIII level was probably not caused by the infection because recent work has shown that bacterial infections do not affect neutrophil Fc␥RIIIb expression. 18 In our group of patients, both neutropenia and low levels of plasma sFc␥RIII reflected a compromised neutrophil defense, predisposing to bacterial infections, but the plasma sFc␥RIII level proved to be a more sensitive indicator. When we eliminated the effect of the ANC on the infection incidence by matching the patients with and without infections for the ANC, the differences in sFc␥RIII levels between the two groups persisted. As in the unmatched group, none of the neutropenic patients with a plasma sFc␥RIII level above 100 AU suffered from an infection in the study period. A similar conclusion can be drawn from the longitudinal data: infections were not reported for patients whose sFc␥RIII levels were above 100 AU during the follow-up period. Apparently, the number of circulating neutrophils alone underestimates the neutrophil defense in these patients. Because the range of sFc␥RIII levels in healthy individuals with normal neutrophil counts is large (30 to 200 AU), with 60% having levels below 100 AU, the interpretation of sFc␥RIII levels below 100 AU in neutropenic patients is complicated. Most of these neutropenic patients may have a level of sFc␥RIII in the lower part of the normal range together with an unusual distribution of neutrophils, reflected by a low number of circulating neutrophils. Low levels of sFc␥RIII can also be expected in the case of low neutrophil Fc␥RIIIb expression. The latter was found in healthy individuals with heterozygous Fc␥RIIIB gene deficiency, a trait that exists in about 10% of the population. 12, 19 Neutrophils from these individuals show half the membrane Fc␥RIIIb expression and half the amount of plasma sFc␥RIII of individuals with two Fc␥RIIIB genes. The lower level of sFc␥RIII in neutropenic patients with infections seems not to be caused by a higher prevalence of heterozygous Fc␥RIIIB gene deficiency because there was no increased prevalence of Fc␥RIIIb-NA(1ϩ2-) or -NA(1-2ϩ) patients. Furthermore, the finding that Fc␥RIIIB gene deficiency is not associated with an increased susceptibility to infections 14 indicates that the gene deletion is probably equally distributed among the infected and noninfected neutropenic groups. Quantitative Southern blotting to determine the number of Fc␥RIIIB genes could definitively settle this question.
In childhood populations, correlations with susceptibility to infections with several microorganisms have been described for both neutrophil Fc␥R polymorphisms. [2] [3] [4] However, we found no differences in Fc␥RIIA-131R/H and Fc␥RIIIB-NA (1, 2) gene distributions between the neutropenic patients with and without bacterial infections, suggesting that, at least in adult neutropenic patients, these polymorphisms do not play a major role in the defense against bacteria.
We determined the test characteristics of sFc␥RIII measurement based on our data. In our group of neutropenic patients, the sensitivity and negative predictive value of an sFc␥RIII level above 100 AU regarding the occurrence of a bacterial infection was 100%. Comparison of this test with the prognostic value of an ANC below 1,000 cells/µL showed that measure- Patients without infections were divided in two groups: one with sFc␥RIII levels above 100 AU (᭺; n ‫؍‬ 9) and one with sFc␥RIII levels below 100 AU (ᮀ; n ‫؍‬ 6). All patients with reported infections had sFc␥RIII below 100 AU (; n ‫؍‬ 6). For personal use only. on July 15, 2017. by guest www.bloodjournal.org From ment of sFc␥RIII is of additional value in the estimation of the infection risk in neutropenia. An ANC below 500/µL was a specific indicator for infection, although sensitivity was weak (specificity and sensitivity of 1.0 and 0.2, respectively). These data suggest that measurement of plasma sFc␥RIII is especially useful in moderate to mild neutropenia (500 to 1,500 cells/µL). The main clinical implication of our data is that prophylactic antibiotics or treatment with G-CSF might be safely omitted in neutropenic patients with sFc␥RIII levels above 100 AU.
Correlations between several disease states and sFc␥RIII levels have been described. [20] [21] [22] However, most of these correlations can be attributed to a decreased bone marrow neutrophil production and consequently low levels of plasma sFc␥RIII. In our patients, the results of bone marrow examinations were similar in the groups with and without infections. This might suggest that the plasma level sFc␥RIII provides a more precise reflection of neutrophil production than does microscopic examination of the bone marrow itself. We only included patients with chronic idiopathic neutropenia in whom production and lifetime of neutrophils were thought to be normal. Our data show that in these patients an sFc␥RIII level above 100 AU can support the clinician in his or her decision to adopt an expectative attitude. Moreover, the hypothesis that plasma sFc␥RIII reflects bone marrow neutrophil production and the results of the present study suggest a possible applicability of sFc␥RIII measurement in more common neutropenias, for example in assessing the severity of bone marrow infiltration in leukemic patients. Prospective evaluation of different patient groups may confirm this assumption.
